Somatostatin analogs in the treatment of neuroendocrine tumors: Current and emerging aspects

Gherardo Mazziotti, Alessandra Mosca, Stefano Frara, Giovanni Vitale, Andrea Giustina

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Introduction: Neuroendocrine tumors (NETs) harbor somatostatin receptors and there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs. Areas covered: This article discusses i) pharmacology of somatostatin and its analogs; ii) antisecretory and anti-proliferative effects of SSAs in NETs; iii) efficacy and safety of emerging therapeutic regimens with first generation SSAs administered at either high doses or in combination with antineoplastic drugs; iv) efficacy and safety of pasireotide and chimeric molecules; v) efficacy of radionuclide therapy of NETs using SSAs. Expert opinion: SSAs are the first-line medical therapy for functioning and non-functioning welldifferentiated NETs. In patients not responder to first generation SSAs, the increase of drug dose over the conventional regimens, the combination of SSAs with other biotherapies or molecular targeted therapies, the switch to pasireotide or the use of SSAs in radionuclide therapy may improve the therapeutic success.

Original languageEnglish
Pages (from-to)1679-1689
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number16
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Neuroendocrine Tumors
Somatostatin
Therapeutics
Radioisotopes
Antineoplastic Combined Chemotherapy Protocols
Molecular Targeted Therapy
Safety
Somatostatin Receptors
Biological Therapy
Expert Testimony
Pharmacology

Keywords

  • Lanreotide
  • Neuroendocrine tumors
  • Octreotide
  • Pasireotide
  • Somatostatin analogs

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Somatostatin analogs in the treatment of neuroendocrine tumors : Current and emerging aspects. / Mazziotti, Gherardo; Mosca, Alessandra; Frara, Stefano; Vitale, Giovanni; Giustina, Andrea.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 16, 01.01.2017, p. 1679-1689.

Research output: Contribution to journalReview article

@article{edd97f9ab81e4e6eb4c015cd7316acba,
title = "Somatostatin analogs in the treatment of neuroendocrine tumors: Current and emerging aspects",
abstract = "Introduction: Neuroendocrine tumors (NETs) harbor somatostatin receptors and there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs. Areas covered: This article discusses i) pharmacology of somatostatin and its analogs; ii) antisecretory and anti-proliferative effects of SSAs in NETs; iii) efficacy and safety of emerging therapeutic regimens with first generation SSAs administered at either high doses or in combination with antineoplastic drugs; iv) efficacy and safety of pasireotide and chimeric molecules; v) efficacy of radionuclide therapy of NETs using SSAs. Expert opinion: SSAs are the first-line medical therapy for functioning and non-functioning welldifferentiated NETs. In patients not responder to first generation SSAs, the increase of drug dose over the conventional regimens, the combination of SSAs with other biotherapies or molecular targeted therapies, the switch to pasireotide or the use of SSAs in radionuclide therapy may improve the therapeutic success.",
keywords = "Lanreotide, Neuroendocrine tumors, Octreotide, Pasireotide, Somatostatin analogs",
author = "Gherardo Mazziotti and Alessandra Mosca and Stefano Frara and Giovanni Vitale and Andrea Giustina",
year = "2017",
month = "1",
day = "1",
doi = "10.1080/14656566.2017.1391217",
language = "English",
volume = "18",
pages = "1679--1689",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "16",

}

TY - JOUR

T1 - Somatostatin analogs in the treatment of neuroendocrine tumors

T2 - Current and emerging aspects

AU - Mazziotti, Gherardo

AU - Mosca, Alessandra

AU - Frara, Stefano

AU - Vitale, Giovanni

AU - Giustina, Andrea

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Neuroendocrine tumors (NETs) harbor somatostatin receptors and there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs. Areas covered: This article discusses i) pharmacology of somatostatin and its analogs; ii) antisecretory and anti-proliferative effects of SSAs in NETs; iii) efficacy and safety of emerging therapeutic regimens with first generation SSAs administered at either high doses or in combination with antineoplastic drugs; iv) efficacy and safety of pasireotide and chimeric molecules; v) efficacy of radionuclide therapy of NETs using SSAs. Expert opinion: SSAs are the first-line medical therapy for functioning and non-functioning welldifferentiated NETs. In patients not responder to first generation SSAs, the increase of drug dose over the conventional regimens, the combination of SSAs with other biotherapies or molecular targeted therapies, the switch to pasireotide or the use of SSAs in radionuclide therapy may improve the therapeutic success.

AB - Introduction: Neuroendocrine tumors (NETs) harbor somatostatin receptors and there is a strong rationale for using somatostatin analogs (SSAs) for treatment of NETs. Areas covered: This article discusses i) pharmacology of somatostatin and its analogs; ii) antisecretory and anti-proliferative effects of SSAs in NETs; iii) efficacy and safety of emerging therapeutic regimens with first generation SSAs administered at either high doses or in combination with antineoplastic drugs; iv) efficacy and safety of pasireotide and chimeric molecules; v) efficacy of radionuclide therapy of NETs using SSAs. Expert opinion: SSAs are the first-line medical therapy for functioning and non-functioning welldifferentiated NETs. In patients not responder to first generation SSAs, the increase of drug dose over the conventional regimens, the combination of SSAs with other biotherapies or molecular targeted therapies, the switch to pasireotide or the use of SSAs in radionuclide therapy may improve the therapeutic success.

KW - Lanreotide

KW - Neuroendocrine tumors

KW - Octreotide

KW - Pasireotide

KW - Somatostatin analogs

UR - http://www.scopus.com/inward/record.url?scp=85034047423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034047423&partnerID=8YFLogxK

U2 - 10.1080/14656566.2017.1391217

DO - 10.1080/14656566.2017.1391217

M3 - Review article

AN - SCOPUS:85034047423

VL - 18

SP - 1679

EP - 1689

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -